News

Zygel Led to Meaningful Behavioral Improvements in Certain Youngsters

Zynerba Pharmaceuticals’ experimental cannabidiol (CBD) gel Zygel results in statistically significant and clinically meaningful reductions in behavioral symptoms in children and adolescents with fragile X syndrome (FXS) and a fully methylated FMR1 gene, according to data from the Phase 2/3 CONNECT-FX trial. DNA methylation is a biochemical modification that…

BPN14770 Improved Men’s Language, Daily Functions

Tetra Therapeutics’ investigational oral therapy BPN14770 safely and effectively improves cognitive function, particularly language-related domains, and daily functioning in men with fragile X syndrome, according to data from a Phase 2 clinical trial. “These results offer hope for patients with fragile X syndrome and their families,” Elizabeth…

Ovid Stops Development and Testing of OV101 for Fragile X

Ovid Therapeutics announced it is discontinuing work to further develop or test OV101 (gaboxadol) as a potential treatment of fragile X syndrome. Although OV101 was found to be safe and well tolerated in multiple clinical trials, its overall efficacy in these studies fell short, Ovid Therapeutics said in a…

Filmmaker Seeks Videos From Fathers of Children with Fragile X

Fathers or male caregivers of children with fragile X syndrome are invited to contribute to a U.K. film project exploring what it’s like to raise someone with learning or behavioral challenges. Olivia Hird, a documentary filmmaker for the nonprofit organization Nip in the Bud, is seeking cellphone videos…

Cardiac to Dental Problems Can Be Early Signal of Fragile X

Physical health is also affected by fragile X syndrome, with problems evident in the heart, digestive system, respiratory tract and even the teeth years before the cause of patients’ intellectual difficulties might be pinpointed, scientists report. Their study, “Artificial intelligence–assisted phenotype discovery of fragile X syndrome in…